Showing 181–192 of 192 resultsSorted by latest
Pharma & Biotech
Novartis had multiple positive Ph3 data readouts for key pipeline assets in Q3 2023, demonstrating the strength of its innovation pipeline across therapeutic areas. Specifically, the company reported clinically meaningful and statistically significant data for iptacopan in treating IgA nephropathy, positioning it for potential accelerated approval.
Tilray Brands EU GMP-certified cultivation and manufacturing facility in Portugal and Germany offers a strategic advantage in these medical cannabis markets compared to peers.
On 30th Nov 2023, Johnson & Johnson MedTech acquired Laminar, a leader in LAA closure technology for stroke prevention in AFib patients. This expands its portfolio and positions it favorably in a rapidly growing market. AFib prevalence is increasing, driving demand for minimally invasive stroke prevention solutions. JNJ MedTech is well- positioned to capitalize on this growth.
MedTech Worldwide sales of $7.5bn increased to 10% with growth of 11.6%(adjusted operational sales grew to 6%) in the U.S. and 8.3% outside of the U.S, driven primarily by electrophysiology products in Interventional Solutions and Abiomed contributed 4.6% to operational growth.
The company achieved an impressive 9% operational revenue growth.
LLY operates as a drug manufacturer and has been successful in developing a number of important drugs for diseases like cancer, diabetes and COVID-19.
The global pharmacy environment has been impacted by labor shortages and changing regulatory requirements.
TWST is the developer of synthetic DNA-based products which is experiencing high demand. These products are being used widely in healthcare industry for sequencing and research.
